BioInvent International AB
3:00 PM - 3:15 PM (EST), Monday, February 6, 2023 ・ Music Box
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
Ticker:
BINV
Exchange:
Nasdaq Stockholm
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Sweden
Year Founded:
Not Provided
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials.
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
